NASDAQ · Biotechnology

Clearmind Medicine Inc. (CMND) Stock

$6.58 -0.30% NASDAQ: CMND Healthcare

Valuation

MetricValue
Price$6.58
Market Cap$1.22M
P/E Ratio-0.51
P/B Ratio0.70
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$480.00
52-Week Low$0.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.29%
ROA-44.32%
ROCE-67.92%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.14
Current Ratio1.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-4.0M$-9.0M$-6.0M$-6.0M$-6.0M
Net Profit$-4.0M$-10.0M$-9.0M$-5.0M$-4.0M
EPS$-473.10$-916.44$-170.07$-6.78$-3.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.0M$1.0M$6.0M$10.0M$6.0M
Total Liabilities$0$3.0M$5.0M$6.0M$5.0M
Cash$4.0M$0$5.0M$9.0M$4.0M
Borrowings$0$0$0$0$2.0M

Latest News

Clearmind Medicine Expands Global IP Portfolio With Hong Kong Patent Filing MT Newswires · Jul 20, 2026 Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market GlobeNewswire · Jul 20, 2026 Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction GlobeNewswire · Jul 17, 2026 Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI GlobeNewswire · Jul 16, 2026 Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial GlobeNewswire · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-5.0M$-6.0M$-7.0M$-5.0M
Investing Cash Flow$0$0$0$0$-1.0M
Financing Cash Flow$0$0$1.0M$6.0M$0
Net Cash Flow$3.0M$-4.0M$5.0M$2.0M$-3.0M
Free Cash Flow$-2.0M$-5.0M$-6.0M$-7.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.21
FCF Yield-88.70%
Quick Ratio4.31
Interest Coverage-649.82
Return 1Y-99.53%
Return 3Y-99.97%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CLDICalidi Biotherapeutics, Inc. $1.03 -0.96% -0.02 $2.66M 0.00%
CNSPCNS Pharmaceuticals, Inc. $5.35 +0.00% -0.23 $7.82M 0.00%
GRIGRI Bio, Inc. $1.74 +3.57% -0.04 $3.80M 0.00%
JAGXJaguar Health, Inc. $4.79 +5.74% 0.00 $2.08M 0.00%

About Clearmind Medicine Inc.

Clearmind Medicine Inc. is led by CEO Adi Zuloff-Shani, employs 4 people, headquartered in CA, publicly traded since 2022.

Clearmind Medicine Inc. (CMND) stock trades at $6.58 with a market capitalization of $1.22M. The stock is valued at a price-to-earnings (P/E) ratio of -0.51, price-to-book of 0.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.71 and $480.00, and currently trades 98.6% below its 52-week high.

On profitability, Clearmind Medicine Inc. generates a return on equity (ROE) of -87.29%, return on capital employed of -67.92%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides